ow-dose prasgurel versus clopidogrel on the dual antiplatelet regimen for intracranial stenting or flow diverter treatment for unruptured cerebral aneurysms: a multi-center randomized controlled trial

Yonsei University Yongin Severance Hospital0 个研究点目标入组 406 人开始时间: 待定最近更新: 2022年3月8日

试验速览

暂无简介。

•? A healthy adult of Korean nationality aged 19 or over and under 75 years of age
•? If a non-ruptured cerebral aneurysm without bleeding within the last 6 months is confirmed by imaging
•? If treatment is planned with a stent or blood flow diverter
•? When the patient himself/herself consented to this study

•? In case of rupture within the last 6 months
•? In case of bleeding requiring treatment including intracranial hemorrhage within the last 3 months
•? If you have already been treated
•? In case of concurrent treatment other than endovascular procedure
•? Contraindications to iodine contrast agents
•? If you are already taking antiplatelet drugs or antithrombotic drugs other than aspirin
•? In case of hypersensitivity to aspirin, prasgurel or clopidogrel
•? In the event that an arrhythmia or blood clot in the heart is detected and antithrombotic medication is required
•? Pregnant or lactating
•? Kidney failure below GFR 60
•? Patients with chronic liver disease with at least 100 IU/L of either AST/ALT in the liver function test
•? If it is judged difficult to follow up after treatment
•? Patients with pathological active bleeding such as peptic ulcer
•? Patients with lactose-containing genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
•? Patients requiring concomitant administration of methotrexate 15 mg or more for one week.
•? Patients with a history of stroke or transient ischemic attack (TIA)
•-Patients continuously taking non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 inhibitors

发起方

Yonsei University Yongin Severance Hospital